Direct contract research solutions supporting analytical development, toxicity profiling, and efficacy assays validated across global pharmacopeias.
OEM In Vitro Test / Research Service for Costa Rica Regulatory Applications Service Protocols
ODM Clinic Study (Phase 1 - Phase 4) Protocols & Regulatory Verification Service Protocols
Establishment of Analysis Methods of Active Ingredient(s) for Botanical APIs Service Protocols
ODM Study & Evaluation of Botanical Active Potency Across Geographic Origins Service Protocols
A strategic convergence of medical device manufacturing, botanical biodiversity, and international regulatory demands driving high-precision in vitro requirements.
Costa Rica’s Free Trade Zones (such as Coyol Free Zone and Global Park) host top-tier multinational medical device manufacturers. The shift from manufacturing disposables to complex Class II and Class III combination devices requires robust in vitro biocompatibility testing (ISO 10993-5 cytotoxicity, hemocompatibility, and irritation assays) without animal dependency.
Holding more than 5% of global terrestrial biodiversity, Costa Rica actively explores native botanicals for pharmaceutical and dermocosmetic uses. Transitioning these natural extracts into validated products requires high-throughput in vitro mechanistic assays to determine anti-inflammatory, antioxidant, and enzymatic inhibition mechanisms before clinical commitment.
Registration of phytopharmaceuticals, cosmetics, and active biomedical devices under the Costa Rican Ministerio de Salud requires verified preclinical safety documentation. In vitro testing protocols established under OECD and GLP criteria streamline dossier acceptance for central American commercialization.
Years of Specialized Bioassay Engineering
In-House Research Scientists & Analytical Chemists
Standardized Formulations Mechanistically Mapped
OECD / ISO 10993 Method Compliance
Global life science enterprises face increased pressure to reduce preclinical turnaround times while maintaining rigorous data integrity.
Across North America, the European Union, and Latin America, procurement directors in pharma and medical technology are executing aggressive New Approach Methodologies (NAMs). The global push to replace, reduce, and refine animal experiments (3Rs) requires manufacturers to deliver cell-based phenotypic screening, membrane permeability assays (e.g., Caco-2 models), and 3D reconstructed tissue systems. MedGence meets this demand through automated cellular testing platforms that generate reproducible, statistically valid batch data for cross-border regulatory submissions.
Disjointed product pipelines frequently separate early bio-activity testing from commercial chemical manufacturing. MedGence bridges this gap by merging CRO screening capabilities with CDMO pilot and commercial extraction facilities. If an active botanical or synthetic compound demonstrates targeted efficacy during in vitro kinase inhibition or cytotoxicity assays, the same process engineering team transitions the compound into batch crystallization, standardized liquid extraction, or encapsulation—reducing commercial launch timelines by up to 40%.
Engineering future-proof cellular models to address complex biocompatibility and clinical translation challenges.
Established 2D immortalized and primary cell lines for cytotoxicity, cytokine response profiling (ELISA, qPCR), and metabolic stability assays. Fully compliant with standard global guidelines.
Transitioning primary lines into organotypic micro-tissues (liver spheroids, reconstructed human epidermis) providing clinically predictive tissue models for toxicity and dermal irritation evaluation.
Integrating mechanical stress, biomimetic flow, and multi-organ interaction (gut-liver-kidney axis) on microfluidic chips to map pharmacokinetics and bio-distribution in real time without animal models.
Machine learning classification of cellular morphological shifts, high-content imaging, and molecular target docking for faster discovery of botanical APIs and synthetic candidates.
Ensuring technical compliance with national and regional regulatory bodies.
We structure test reports according to RTCA (Reglamento Técnico Centroamericano) requirements. Our documentation directly supports registration dossiers for phytotherapeutic products, cosmetics, and medical materials.
Standard operating procedures cover international transport of specialized biologics, botanical extracts, and cell lysates. Direct logistics ensure temperature stability from San José manufacturing corridors to our centralized research centers.
All research programs operate under formal Non-Disclosure Agreements (NDAs). Proprietary manufacturing processes, synthetic routes, and extraction parameters remain protected through encrypted data management and isolated research pipelines.
Key information regarding bioassay selection, turnaround timelines, and cross-border regulatory acceptance.
Complete research and manufacturing capabilities supporting analytical, preclinical, and clinical pipelines.
Whether you require ISO 10993 cytotoxicity assays for medical devices or mechanistic cell models for botanical APIs in Costa Rica, our scientific team is ready to assist.
Send Inquiry Now